PriceTargets.com logo

NASDAQ:LIFE - aTyr Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.50
  • Forecasted Upside: 136.49 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.44 As of 03/4/2021 05:54 PM ET
▲ +0.12 (2.78%)
1 month | 3 months | 12 months
Get New aTyr Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LIFE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LIFE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$10.50
▲ +136.49% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for aTyr Pharma in the last 3 months. The average price target is $10.50, with a high forecast of $13.00 and a low forecast of $8.00. The average price target represents a 136.49% upside from the last price of $4.44.
Buy
The current consensus among 2 polled investment analysts is to buy stock in aTyr Pharma. This rating has held steady since February 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2020OppenheimerReiterated RatingBuyLow
i
8/17/2020HC WainwrightUpgradeNeutral ➝ Buy$13.00High
i
Rating by J. Pantginis at HC Wainwright
6/16/2020OppenheimerReiterated RatingBuy$8.00High
i
5/13/2020OppenheimerReiterated RatingBuy$8.00High
i
4/21/2020HC WainwrightReiterated RatingHoldHigh
i
Rating by J. Pantginis at HC Wainwright
3/27/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
i
Rating by Joseph Pantginis at HC Wainwright
3/4/2020Roth CapitalInitiated CoverageBuy$15.00High
i
Rating by Z. Jallah at Roth Capital
3/2/2020OppenheimerInitiated CoverageOutperform$8.00Low
i
1/10/2020HC WainwrightReiterated RatingBuy$8.00Low
i
Rating by Joseph Pantginis at HC Wainwright
12/13/2019HC WainwrightReiterated RatingBuy$8.00High
i
Rating by Joseph Pantginis at HC Wainwright
11/15/2019HC WainwrightReiterated RatingBuy$8.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
11/5/2019HC WainwrightInitiated CoverageBuy$8.00 ➝ $8.00High
i
Rating by J. Pantginis at HC Wainwright
8/30/2019CitigroupSet Price TargetHold$4.00Low
i
Rating by Joel Beatty at Citigroup Inc.
3/26/2019William BlairReiterated RatingMarket PerformLow
i
Rating by Y. Xu at William Blair
10/8/2018Piper Jaffray CompaniesLower Price TargetOverweight$42.00 ➝ $25.20Low
i
8/16/2018CitigroupUpgradeSell ➝ Neutral$14.00 ➝ $10.50High
i
8/15/2018BMO Capital MarketsLower Price TargetMarket Perform ➝ Hold$28.00 ➝ $14.00High
i
Rating by Matthew Luchini at BMO Capital Markets
5/14/2018CitigroupDowngradeNeutral ➝ SellHigh
i
5/14/2018Piper Jaffray CompaniesReiterated RatingOverweight$42.00High
i
2/14/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
i
9/7/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$98.00High
i
8/15/2017BMO Capital MarketsSet Price TargetHold$56.00High
i
Rating by Matthew Luchini at BMO Capital Markets
5/24/2017BMO Capital MarketsReiterated RatingHoldLow
i
Rating by Matthew Luchini at BMO Capital Markets
3/20/2017CitigroupBoost Price TargetNeutral$42.00 ➝ $56.00Medium
i
3/18/2017BMO Capital MarketsSet Price TargetHold$56.00Medium
i
Rating by Matthew Luchini at BMO Capital Markets
3/18/2017JPMorgan Chase & Co.Reiterated RatingHoldMedium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/15/2016BMO Capital MarketsReiterated RatingMarket Perform$112.00 ➝ $56.00N/A
i
Rating by Matthew Luchini at BMO Capital Markets
12/13/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$39.90N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/6/2016BMO Capital MarketsSet Price TargetHold$112.00N/A
i
Rating by Matthew Luchini at BMO Capital Markets
8/16/2016CitigroupBoost Price TargetNeutral$42.00 ➝ $56.00N/A
i
8/11/2016JPMorgan Chase & Co.Lower Price TargetOverweight$210.00 ➝ $140.00N/A
i
5/12/2016BMO Capital MarketsReiterated RatingHoldN/A
i
Rating by Matthew Luchini at BMO Capital Markets
4/11/2016BMO Capital MarketsInitiated CoverageMarket PerformN/A
i
3/31/2016William BlairDowngradeOutperform ➝ Market PerformN/A
i
Rating by Y. Xu at William Blair
(Data available from 3/4/2016 forward)
aTyr Pharma logo
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan; and a research collaboration with the Medical University of South Carolina to develop therapeutic antibodies that selectively target specific NRP2 isoforms. The company was founded in 2005 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $4.44
$4.21
$4.48

50 Day Range

MA: $4.78
$3.53
$8.06

52 Week Range

Now: $4.44
$2.13
$8.33

Volume

524,087 shs

Average Volume

1,170,288 shs

Market Capitalization

$45.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.17

Frequently Asked Questions

What sell-side analysts currently cover shares of aTyr Pharma?

The following Wall Street sell-side analysts have issued research reports on aTyr Pharma in the last year: HC Wainwright, Oppenheimer Holdings Inc., Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for LIFE.

What is the current price target for aTyr Pharma?

2 Wall Street analysts have set twelve-month price targets for aTyr Pharma in the last year. Their average twelve-month price target is $10.50, suggesting a possible upside of 136.5%. HC Wainwright has the highest price target set, predicting LIFE will reach $13.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $8.00 for aTyr Pharma in the next year.
View the latest price targets for LIFE.

What is the current consensus analyst rating for aTyr Pharma?

aTyr Pharma currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LIFE will outperform the market and that investors should add to their positions of aTyr Pharma.
View the latest ratings for LIFE.

What other companies compete with aTyr Pharma?

Other companies that are similar to aTyr Pharma include Thermo Fisher Scientific, Illumina, Agilent Technologies, Mettler-Toledo International, Bio-Rad Laboratories, Waters, PerkinElmer, Bio-Techne, Charles River Laboratories International, Bruker, Pacific Biosciences of California, Luminex, Fluidigm, Harvard Bioscience and BG Medicine.

How do I contact aTyr Pharma's investor relations team?

aTyr Pharma's physical mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is 858-731-8389 and its investor relations email address is [email protected] The official website for aTyr Pharma is www.atyrpharma.com.